The National Institute for Health and Care Excellence

New take at home drug recommended for people with chronic lymphocytic leukaemia

NICE has recommended a new take‑at‑home tablet for some people with chronic lymphocytic leukaemia whose disease has returned after treatment. The draft guidance could give patients greater choice and ...
The National Institute for Health and Care Excellence

‘Trojan horse’ treatment recommended for people with multiple myeloma

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
The National Institute for Health and Care Excellence

Have your say on NICE’s adoption of the new EQ-5D-5L value set

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...
National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

Fezolinetant (also called Veoza and made by Astellas Pharma) is recommended to treat moderate to severe symptoms in final draft NICE guidance. Hot flushes and night sweats can hugely affect daily life ...
National Institute for Health and Care Excellence

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
National Institute for Health and Care Excellence

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...
National Institute for Health and Care Excellence

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a simple discount patient access scheme for isatuximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess ...
National Institute for Health and Care Excellence

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over

There is a simple discount patient access scheme for idebenone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...
National Institute for Health and Care Excellence

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

There is a simple discount patient access scheme for capivasertib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...